Monalizumab
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A) . Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC) .
Product Specifications
CAS Number
1228763-95-8
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Chk | IFNAR
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1106637-01 0.02 mg (E-Coli)
Recombinant Caulobacter crescentus Pyrimidine monooxygenase RutA (rutA)
Sign In for Pricing
View Details 
MBS1106637-02 0.02 mg (Yeast)
Recombinant Caulobacter crescentus Pyrimidine monooxygenase RutA (rutA)
Sign In for Pricing
View Details MBS1106637-03 0.1 mg (E-Coli)
Recombinant Caulobacter crescentus Pyrimidine monooxygenase RutA (rutA)
Sign In for Pricing
View Details MBS1106637-04 0.1 mg (Yeast)
Recombinant Caulobacter crescentus Pyrimidine monooxygenase RutA (rutA)
Sign In for Pricing
View Details MBS1106637-05 0.02 mg (Baculovirus)
Recombinant Caulobacter crescentus Pyrimidine monooxygenase RutA (rutA)
Sign In for Pricing
View Details 
MBS1106637-06 0.02 mg (Mammalian-Cell)
Recombinant Caulobacter crescentus Pyrimidine monooxygenase RutA (rutA)
Sign In for Pricing
View Details